Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Metrics to compare | ROVI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipROVIPeersSector | |
---|---|---|---|---|
P/E Ratio | 19.4x | 18.0x | −0.5x | |
PEG Ratio | −1.17 | 0.23 | 0.00 | |
Price / Book | 4.6x | 2.0x | 2.6x | |
Price / LTM Sales | 3.5x | 2.2x | 3.0x | |
Upside (Analyst Target) | 47.8% | 25.4% | 56.3% | |
Fair Value Upside | Unlock | 21.7% | 10.0% | Unlock |